Since its foundation in 2012, Plexense, Inc. has
specialized in the development and production of rapid
and cost-effective immunoassay platform for clinical,
food and life sciences testing.
Our proprietary technology, ACCEL ELISA®, provides up to 40X increase in sensitivity compared to conventional techniques.
ACCEL ELISA excels in screening small molecule,
hormones, residual compounds or biomarkers with its
high-throughput immunoassay, outperforming
traditional ELISA, mass spectrometry and HPLC
(High-Performance Liquid Chromatography).
We are constantly developing new applications
by working with government agencies, commercial organizations, and academic partners.
Since 2018, Plexense, Inc. has been working as collaboration partners with Mayo Clinic and the US Department of Agriculture-ARS (Agricultural Research Service) to develop advanced early disease detection kits utilizing its proprietary ACCEL ELISA® technology.
Today, it is working under a joint development agreement with KRIBB (Korea Research Institute of Bioscience and Biotechnology) and the Korea CDC to develop various antibody tests related to MERS, Influenza, and COVID-19.
Plexense, Inc. headquartered in Korea with primary R&D and production in Korea, as well. It also has an affiliate company under the name Plexense BIO, Inc. in California and Florida, USA.